Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

The global age-standardized prevalence of AD and other dementias increased from 672 (95% uncertainty interval: 589 to 764) per 100,000 population in 1990 to 694 (603 to 794) per 100,000 population in 2021, with AAPCs of 0.09% (95% confidence interval: 0.06% to 0.11%). However, age-standardized mortality did not change (AAPCs: 0.00% [-0.01% to 0.02%]) and age-standardized DALYs slightly increased from 446 (206 to 958) to 451 (213 to 950) per 100,000 population (AAPCs: 0.01% [0.00% to 0.03%]). While the highest prevalence remained in population aged 65-69 and the countries with a high-middle sociodemographic index (SDI) such as East Asia (e.g., China), the highest mortality and DALYs were found in population aged 65-69 and the countries with a low-middle SDI such as South Asia (e.g., India). High fasting plasma glucose ranked the highest risk factor for DALYs during 1990-2021. The global increased prevalence of AD and other dementias may partly be attributed to population aged 65-69 in the countries with a high-middle SDI (e.g., China), whereas mortality and DALY ratio of population aged 65-69 from the countries with a low-middle SDI (e.g., India) is most significantly growing. Controlling of high fasting plasma glucose may be needed for the reduction of DALYs from AD and other dementias.

What this study adds

Evidence grade: Low

Global age-standardized prevalence of Alzheimer's and other dementias rose slightly from 1990 to 2021, while age-standardized mortality did not change and DALYs increased slightly. Reported effect size: 0.09%; 0.06% to 0.11%; 0.00%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Wang, R. (2025). Global Burden of Alzheimer’s Disease and Other Dementias during 1990–2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study. Neuroepidemiology. https://doi.org/10.1159/000543578

Vancouver

Wang R. Global Burden of Alzheimer’s Disease and Other Dementias during 1990–2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study. Neuroepidemiology. 2025. doi:10.1159/000543578. PMID: 39837288.

BibTeX

@article{wang2025-39837288,
  author  = {Wang, Renxi},
  title   = {{Global Burden of Alzheimer’s Disease and Other Dementias during 1990–2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study}},
  journal = {Neuroepidemiology},
  year    = {2025},
  doi     = {10.1159/000543578},
  pmid    = {39837288},
  url     = {https://doi.org/10.1159/000543578}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Global age-standardized prevalence of Alzheimer's and other dementias rose slightly from 1990 to 2021, while age-standardized mortality did not change and DALYs increased slightly. High fasting plasma glucose ranked as the highest risk factor for DALYs, suggesting its control may be needed to reduce the dementia burden.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 3 of 5; Impact for its field and year 5 of 6; Cited by studies here 1 of 6; Still being cited 2 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Neuroepidemiology)
Journal's citation record 1 / 4 Neuroepidemiology: journal h-index 125 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 40 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 13.3 citations a year over 3 year(s) since 2025
Impact for its field and year 5 / 6 Cited 25.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 2 / 4 Cited 40 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Renxi Wang: h-index 36 (OpenAlex, whole career)
Institution's track record 0 / 3 Capital Medical University: institution h-index 643 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 39837288)
Free to read 2 / 2 Free to read
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →